These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 27928947)

  • 1. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
    Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
    Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
    Kappel BA; Marx N; Federici M
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Protection with Anti-hyperglycemic Agents.
    Deedwania P; Acharya T
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):249-257. PubMed ID: 30767126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
    Kaul S
    Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
    Santamarina M; Carlson CJ
    BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC; Borghi C; Consoli A; Volpe M
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
    Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
    Rosenstock J; Marx N; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Bluhmki E; Patel S; Johansen OE; Woerle HJ
    Diab Vasc Dis Res; 2013 Jul; 10(4):289-301. PubMed ID: 23449634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
    Scheen AJ
    Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.